
Claims

1. Use of a compound 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7 naphthyridine of formula (I)



(I)

in the manufacture of a medicament for the treatment of a hyper-proliferative disease, wherein the medicament is to be administered in an amount of from 60 mg to 160 mg per day.

2. The use according to claim 1, wherein the compound of formula (I) is to be administered in an amount of from 80 mg to 160 mg per day.

3. The use according to claim 1, wherein the compound of formula (I) is to be administered in an amount of 80 mg per day.

4. The use according to claim 3, wherein the compound of formula (I) is to be administered in an amount of 40 mg (BID).

5. The use according to claim 4, wherein the dosing schedule is 3 days on/4 days off.

6. The use according to any one of claims 1 to 5, wherein the compound of formula (I) is comprised in a pharmaceutical composition, the pharmaceutical composition comprising the compound of formula (I) in an amount of 40 mg and at least one pharmaceutically acceptable excipient.

7. The use according to any one of claims 1 to 6, wherein in said use, said hyper-proliferative disease is psoriasis, a keloid, a hyperplasia affecting the skin, benign prostate hyperplasia (BPH), a solid tumour such as a cancer of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid, or a distant metastasis thereof.